Neumora Therapeutics (NMRA) Common Equity (2022 - 2026)

Neumora Therapeutics' Common Equity history runs 5 years deep, the most recent figure standing at $70.7 million for Q1 2026.

• In Q1 2026, Common Equity fell 69.05% year-over-year to $70.7 million; the TTM figure through Mar 2026 stood at $70.7 million (down 69.05% YoY), while the FY2025 annual figure was $103.9 million, down 63.82% from the prior year.
• Common Equity was $70.7 million for Q1 2026 at Neumora Therapeutics, down from $103.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $512.7 million in Q3 2023 to a low of -$513.5 million in Q2 2023.
• Historically, Common Equity has averaged $83.5 million across 5 years, with a median of $182.9 million in 2025.
• The sharpest annual moves came in 2023 and 2026: Common Equity surged 221.49% in 2023, then sank 69.05% in 2026.
• A 5-year view of Common Equity shows it stood at -$446.8 million in 2022, then surged by 204.97% to $469.1 million in 2023, then tumbled by 38.8% to $287.1 million in 2024, then slumped by 63.82% to $103.9 million in 2025, then tumbled by 31.95% to $70.7 million in 2026.
• The last three Common Equity figures came in at $70.7 million (Q1 2026), $103.9 million (Q4 2025), and $132.2 million (Q3 2025), per Business Quant data.